Charles River to Acquire Frontage's Bioanalysis and DMPK Businesses in Estimated $470 Million Cash Deal
Charles River Laboratories agreed to buy Frontage Holdings' bioanalysis and DMPK operations in Exton, Pennsylvania for an estimated $470 million in cash, the company said in an 8-K filed Monday, a move to expand its clinical-stage drug testing work.
The deal also includes additional payments of up to $75 million, contingent on the future performance of the acquired businesses. Charles River expects to close in the first half of 2027, subject to shareholder and regulatory approvals.
The two Exton sites, which include a CLIA-certified central laboratory, provide bioanalysis, biomarker and drug metabolism and pharmacokinetics testing for large and small molecules, primarily supporting clinical development programs. They employ an estimated 340 people, the company said.
"The planned acquisition accelerates our strategy to expand our bioanalysis capabilities and enhance our offering in an attractive, high-growth market," Chief Executive Birgit Girshick said.
Why clinical work matters
Clinical-phase testing currently accounts for an estimated 15% of Charles River's bioanalysis revenue, the company said, while the majority of Frontage's bioanalysis revenue in 2025 came from clinical development. Charles River expects the bioanalysis market to grow from an estimated $6 billion in 2026 to an estimated $8 billion to $9 billion in 2031.
The businesses being acquired represented an estimated 40% of Frontage's total 2025 revenue of $256.7 million, according to the release.
Earnings impact and financing
Charles River expects the deal to be neutral to non-GAAP earnings per share in 2027 and accretive after that. It plans to fund the purchase and fees through its credit facility and available cash, and will report the businesses in its Discovery and Safety Assessment segment.
A take-private first
Frontage is listed on the Stock Exchange of Hong Kong. Charles River has formed a consortium with Frontage's controlling shareholder, Hongkong Tigermed, and Frontage Chairman Dr. Song Li to take the company private through a court-sanctioned scheme of arrangement.
After the privatization, Frontage will be split up. Charles River will keep the Exton bioanalysis and DMPK businesses, and Frontage's remaining businesses will go to Tigermed and Dr. Song Li. Completion requires approvals including a Tigermed shareholder vote, Frontage shareholder approval and sanction by the Grand Court of the Cayman Islands.
Sources
- Charles River Laboratories Form 8-K with press release (Exhibit 99.1) on planned acquisition of Frontage's bioanalysis and DMPK businesses, filed Nov. 9, 2026 (accession 0000950103-26-017127)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence. SI may make mistakes.